Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9422984 | 0.90 | KDM4E (0.53) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL9422809 | 0.90 | KDM4E (0.49) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL9422780 | 0.89 | KDM4E (0.52) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL9422757 | 0.88 | KDM4E (0.52) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL6170644 | 0.86 | AGTR2 (0.53) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL9422752 | 0.83 | AGTR1 (0.61) | AGTR1AGTR2 | |
| SCHEMBL9422841 | 0.83 | KDM4E (0.54) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL9754985 | 0.83 | AGTR2 (0.54) | AGTR1AGTR2 | |
| SCHEMBL9422790 | 0.82 | KDM4E (0.48) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL9422775 | 0.80 | KDM4E (0.53) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5294631-A | Substituted benzimidazoles useful as angiotension II receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-15 | — | — | US | claimed |
| EP-0525129-A4 | SUBSTITUTED BENZIMIDAZOLES | — | 1993-03-24 | — | — | EP | claimed |
| EP-0525129-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-03 | — | — | EP | claimed |
| WO-1991016313-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-31 | — | — | WO | claimed |
| US-20030187044-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-10-02 | — | — | US | disclosed |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| US-20030096851-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-05-22 | — | — | US | disclosed |
| US-20030069293-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2003-04-10 | — | — | US | disclosed |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2003-03-13 | — | — | US | disclosed |
| US-20030004201-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-01-02 | — | — | US | disclosed |
| US-20020160985-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2002-10-31 | — | — | US | disclosed |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | SMITHKLINE BEECHAM P.1.C. | 2002-09-19 | — | — | US | disclosed |
| WO-1992010183-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010186-A1 | USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010097-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010185-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010184-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010182-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010188-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HEMORRAGIC STROKE | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1991016313-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160985-A1 | Medicament | AGTR2, AGTR1, ACE | KDM4E 4622/4885ALDH1A1 932/4885LMNA 1828/4885 |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | AGTR2, AGTR1, AGT | KDM4E 4261/4885ALDH1A1 1058/4885LMNA 2596/4885 |
| US-20030187044-A1 | Medicament | AGTR2, AGTR1, ACE | KDM4E 3340/4885ALDH1A1 2570/4885LMNA 4293/4885 |
| US-20030004201-A1 | Medicament | AGTR2, AGTR1, ACE | KDM4E 4227/4885ALDH1A1 1824/4885LMNA 1660/4885 |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | AGTR1, AGTR2, AGT | KDM4E 3322/4885ALDH1A1 650/4885LMNA 1318/4885 |
| US-20030096851-A1 | Medicament | AGTR2, AGTR1, ACE | KDM4E 3340/4885ALDH1A1 2570/4885LMNA 4293/4885 |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | AGTR2, AGTR1, ACE | KDM4E 2682/4885ALDH1A1 782/4885LMNA 3293/4885 |
| US-20030069293-A1 | Medicament | AGTR2, AGTR1, ACE | KDM4E 4622/4885ALDH1A1 932/4885LMNA 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.